베타
임상 레이더 AI
하나의 임상시험이 필터 기준과 일치합니다.
카드 뷰
검색으로 돌아가기

Continuous Glucose Monitoring Devices in Hospitalized Veterans With Diabetes 218 참전 용사 신규 요법

진행중, 모집종료
임상시험 세부 정보는 주로 영어로 제공됩니다. 하지만 임상 레이더 AI가 도와드릴 수 있습니다! '임상시험 설명'를 클릭하여 선택한 언어로 임상시험 정보를 확인하고, 이에 대해 AI와 논의해 보세요.
임상시험 NCT03508934은(는) 제2형 당뇨병, 저혈당증에 대해 알아보는 중재연구입니다. 현재 상태는 진행중, 모집종료이며, 연구는 2018년 7월 1일에 시작되어 218명의 참여자를 모집하고 있습니다. VA Office of Research and Development이(가) 진행하며, 2026년 4월 30일까지 완료될 예정입니다. ClinicalTrials.gov의 가장 최근 정보는 2026년 1월 7일에 갱신되었습니다.
간단한 개요
More than 25% of the patients admitted in the general wards have a history of Diabetes Mellitus (DM). Up to 30% of the hospitalized diabetics develop hypoglycemia (low glucose values); a condition that is associated with seizures, cardiac arrhythmias, and even death. In Veterans, the prevalence is disproportionally higher. It is estimated that 40-50% of hospitalized Veterans are diabetics. In this clinical trial the ...더 보기
상세한 설명
More than 25% of patients admitted to general wards/non Intensive Care Unit (non-ICU) setting have a history of Diabetes Mellitus (DM); and as for 2012, $125 billion dollars were costs associated with hospitalization of diabetics in the United States (US). Up to 30% of the hospitalized diabetics develop hypoglycemia, a condition that is associated with higher hospital charges, prolonged length of stay, and increased ...더 보기
공식 제목

Continuous Glucose Monitoring in Insulin Treated Hospitalized Veterans With DM2 at Higher Risk for Hypoglycemia

질환명
제2형 당뇨병저혈당증
출판물
이 임상시험에 대해 발표된 과학 논문 및 연구 자료.
기타 연구 식별자
  • ENDA-022-17F
  • CX001825-01 (기타 보조금/자금 번호) (VA Office of Research and Development)
NCT 번호
NCT03508934
실제 연구 시작일
2018-07-01
최신 업데이트 게시
2026-01-07
예상 연구 완료일
2026-04-30
계획된 등록 인원
218
연구종류
중재연구
단계/상
해당 없음
상태
진행중, 모집종료
키워드
Diabetes Mellitus, Type 2
hypoglycemia
Continuous Glucose Monitoring
hospital
inpatient
주요 목적
예방
설계 할당
무작위배정
중재 모델
평행설계
맹검 (마스킹)
없음 (오픈 라벨)
시험군 / 개입
참가자 그룹/시험군개입/치료
활성 대조군Intervention group (Continuous Glucose Monitroring and POC)
Hospitalized patients with DM2 will be monitored with Glucose Telemetry System (GTS) and Point of Care (POC) finger-stick blood glucose levels with application of hypoglycemia prevention protocol (activated based the GTS lower glucose alarms)
GTS (Continuous Glucose Monitoring)
Hospitalized patients with DM2 will be monitored with Glucose Telemetry System (GTS)
POC (Point of Care)
Hospitalized patients with DM2 will be monitored with POC (Point of Care) blood glucose levels.
위약 대조군Control group (Point of Care-POC)
Hospitalized patients with DM2 will be monitored with POC blood glucose levels and application of hypoglycemia prevention protocol (activated based the POC values)
POC (Point of Care)
Hospitalized patients with DM2 will be monitored with POC (Point of Care) blood glucose levels.
주요결과변수
결과변수측정값 설명시간 범위
Decrease in hypoglycemia during the hospitalization
GTS and the application of the hypoglycemia prevention protocol will lead to a decrease in hypoglycemia in the hospital
Through study completion-hospitalization (average length of stay at the hospital of 4-6 days)
참여 도우미
적격성 기준

연령대
성인, 노인
최소 연령
21 Years
참여 가능한 성별
전체

  • Veterans with history of DM2 managed with insulin (either basal bolus, basal only or basal with per os DM medications), admitted to the Baltimore VA Medical Center, who have at

    • least 1 risk factor of hypoglycemia

  • Veterans with history of type 1 DM.
  • Veterans with history of DM2 managed with diet or any combination of oral antidiabetic drugs only.
  • Veterans hospitalized with significant hyperglycemia or diabetic ketoacidosis
  • Pregnant Veterans
  • Veterans receiving glucocorticosteroids in doses (equivalent) to 20 mg of hydrocortisone/day
  • Veterans that are expected to require a hospital stay <3 days will also be excluded
VA Office of Research and Development logoVA Office of Research and Development
연락처 정보가 없습니다.
1 1개국에 임상시험 장소

Maryland

Baltimore VA Medical Center VA Maryland Health Care System, Baltimore, MD, Baltimore, Maryland, 21201, United States